Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease

Backgrounds: Metabolic syndrome is a subclinical status in promoting atherosclerotic cardiovascular disease and type 2 diabetes mellitus. The significance of metabolic syndrome and pathophysiology in chronic kidney disease is not investigated. Methods: We enrolled adult patients with CKD stages 3 to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fan-Chi Chang, Ming-Ching Lee, Chih-Kang Chiang, Jia-Sin Liu, Tai-Shuan Lai, Wen-Chih Chiang, Yung-Ming Chen, Tzong-Shinn Chu
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Metabolic syndrome Angiopoietin-2 Chronic kidney disease Inflammation Endothelial dysfunction Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5d54c016601a4c5380422afd6e6fe57a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d54c016601a4c5380422afd6e6fe57a
record_format	dspace
spelling	oai:doaj.org-article:5d54c016601a4c5380422afd6e6fe57a2021-12-02T04:59:10ZAngiopoietin-2 is associated with metabolic syndrome in chronic kidney disease0929-664610.1016/j.jfma.2021.05.003https://doaj.org/article/5d54c016601a4c5380422afd6e6fe57a2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0929664621001881https://doaj.org/toc/0929-6646Backgrounds: Metabolic syndrome is a subclinical status in promoting atherosclerotic cardiovascular disease and type 2 diabetes mellitus. The significance of metabolic syndrome and pathophysiology in chronic kidney disease is not investigated. Methods: We enrolled adult patients with CKD stages 3 to 5 from December 2006 to December 2007. Metabolic syndrome was defined by the US National Cholesterol Education Programme Adult Treatment Panel III guidelines. Plasma levels of angiogenic growth factors were measured. Univariate and multivariate logistic regression analyses were used. Results: Total 451 patients were analyzed with median estimated glomerular filtration rate of 27.0 ml/min per 1.73m2 (interquartile range 14.3–41.3). Patients with metabolic syndrome were older (P = 0.002), had higher percentage using diuretics (P = 0.002) but lower percentage using pentoxifylline (P = 0.017). Patients with metabolic syndrome had higher levels of high-sensitivity C-reactive protein (P < 0.0001), uric acid (P = 0.009) and angiopoietin-2 (P = 0.001). Multivariate logistic regression analyses revealed significant association between plasma levels of angiopoietin-2 and metabolic syndrome (P = 0.042). Conclusion: The prevalence of metabolic syndrome in advanced CKD was higher than general population. CKD patients with metabolic syndrome had higher levels of high-sensitivity C-reactive protein, uric acid and angiopoietin-2. Plasma levels of angiopoietin-2 were significantly associated with metabolic syndrome in patients with CKD. Metabolic syndrome in CKD may be not only a prognostic factor but also an interventional target, possibly through ameliorating inflammation. Prospective and interventional studies are necessary to establish the pathophysiology.Fan-Chi ChangMing-Ching LeeChih-Kang ChiangJia-Sin LiuTai-Shuan LaiWen-Chih ChiangYung-Ming ChenTzong-Shinn ChuElsevierarticleMetabolic syndromeAngiopoietin-2Chronic kidney diseaseInflammationEndothelial dysfunctionMedicine (General)R5-920ENJournal of the Formosan Medical Association, Vol 120, Iss 12, Pp 2113-2119 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Metabolic syndrome Angiopoietin-2 Chronic kidney disease Inflammation Endothelial dysfunction Medicine (General) R5-920
spellingShingle	Metabolic syndrome Angiopoietin-2 Chronic kidney disease Inflammation Endothelial dysfunction Medicine (General) R5-920 Fan-Chi Chang Ming-Ching Lee Chih-Kang Chiang Jia-Sin Liu Tai-Shuan Lai Wen-Chih Chiang Yung-Ming Chen Tzong-Shinn Chu Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
description	Backgrounds: Metabolic syndrome is a subclinical status in promoting atherosclerotic cardiovascular disease and type 2 diabetes mellitus. The significance of metabolic syndrome and pathophysiology in chronic kidney disease is not investigated. Methods: We enrolled adult patients with CKD stages 3 to 5 from December 2006 to December 2007. Metabolic syndrome was defined by the US National Cholesterol Education Programme Adult Treatment Panel III guidelines. Plasma levels of angiogenic growth factors were measured. Univariate and multivariate logistic regression analyses were used. Results: Total 451 patients were analyzed with median estimated glomerular filtration rate of 27.0 ml/min per 1.73m2 (interquartile range 14.3–41.3). Patients with metabolic syndrome were older (P = 0.002), had higher percentage using diuretics (P = 0.002) but lower percentage using pentoxifylline (P = 0.017). Patients with metabolic syndrome had higher levels of high-sensitivity C-reactive protein (P < 0.0001), uric acid (P = 0.009) and angiopoietin-2 (P = 0.001). Multivariate logistic regression analyses revealed significant association between plasma levels of angiopoietin-2 and metabolic syndrome (P = 0.042). Conclusion: The prevalence of metabolic syndrome in advanced CKD was higher than general population. CKD patients with metabolic syndrome had higher levels of high-sensitivity C-reactive protein, uric acid and angiopoietin-2. Plasma levels of angiopoietin-2 were significantly associated with metabolic syndrome in patients with CKD. Metabolic syndrome in CKD may be not only a prognostic factor but also an interventional target, possibly through ameliorating inflammation. Prospective and interventional studies are necessary to establish the pathophysiology.
format	article
author	Fan-Chi Chang Ming-Ching Lee Chih-Kang Chiang Jia-Sin Liu Tai-Shuan Lai Wen-Chih Chiang Yung-Ming Chen Tzong-Shinn Chu
author_facet	Fan-Chi Chang Ming-Ching Lee Chih-Kang Chiang Jia-Sin Liu Tai-Shuan Lai Wen-Chih Chiang Yung-Ming Chen Tzong-Shinn Chu
author_sort	Fan-Chi Chang
title	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
title_short	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
title_full	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
title_fullStr	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
title_full_unstemmed	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
title_sort	angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/5d54c016601a4c5380422afd6e6fe57a
work_keys_str_mv	AT fanchichang angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT mingchinglee angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT chihkangchiang angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT jiasinliu angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT taishuanlai angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT wenchihchiang angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT yungmingchen angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease AT tzongshinnchu angiopoietin2isassociatedwithmetabolicsyndromeinchronickidneydisease
_version_	1718400890621132800

Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease

Ejemplares similares